Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
Gide TN, Pires da Silva I, Quek C, Ferguson PM, Batten M, Shang P, et al. Clinical and molecular heterogeneity in patients with innate resistance to anti-PD-1 +/− anti-CTLA-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets. Cancers. 2021;13:3186.
Google Scholar
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer. 2019;19:133–50.
Cho SF, Anderson KC, Tai YT. Microenvironment is a key determinant of immune checkpoint inhibitor response. Clin Cancer Res. 2022;28:1479–81.
Google Scholar
Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nat Rev Immunol. 2018;18:423–37.
Pick R, Wang C, Zeng Q, Melis Gül Z, Scheiermann C. Circadian rhythms in anticancer immunity: mechanisms and treatment opportunities. Annu Rev Immunol. 2024;42:83–102.
Long JE, Drayson MT, Taylor AE, Toellner KM, Lord JM, Phillips AC. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial. Vaccine. 2016;34:2679–85.
Google Scholar
Phillips AC, Gallagher S, Carroll D, Drayson M. Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. Psychophysiology. 2008;45:663–6.
Google Scholar
Zhang H, Liu Y, Liu D, Zeng Q, Li L, Zhou Q, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 2021;31:1215–7.
Printezi MI, Kilgallen AB, Štibler U, Teske AJ, Cramer MJ, G Sluijter JP, et al. Toxicity and efficacy of chronomodulated chemotherapy: a systematic review [Internet]. Rev Lancet Oncol. 2022;23, Available from: www.thelancet.com/oncology.
Shuboni-Mulligan DD, Breton G, Smart DD, Gilbert M, Armstrong TS. Radiation chronotherapy—clinical impact of treatment time-of-day: a systematic review. J Neuro-Oncol. 2019;145:415–27.
Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus. 2023;20:722–31.
Google Scholar
Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, et al. Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2023;21:530–6.
Google Scholar
Gonçalves L, Gonçalves D, Esteban-Casanelles T, Barroso T, Soares de Pinho I, Lopes-Brás R, et al. Immunotherapy around the clock: impact of infusion timing on stage IV melanoma outcomes. Cells. 2023;12:2068.
Google Scholar
Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers. 2022;14:896.
Google Scholar
Patel JS, Woo Y, Draper A, Jansen CS, Carlisle JW, Innominato PF, et al. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. J Immunother Cancer. 2024;12:e008011.
Google Scholar
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777–86.
Google Scholar
Rousseau A, Tagliamento M, Auclin E, Aldea M, Frelaut M, Levy A, et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023;182:107–14.
Google Scholar
Yeung C, Kartolo A, Tong J, Hopman W, Baetz T. Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma. Immunotherapy. 2023;15:819–26.
Google Scholar
Hirata T, Uehara Y, Hakozaki T, Kobayashi T, Terashima Y, Watanabe K, et al. Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC. JTO Clin Res Rep. 2024;5:100659.
Google Scholar
Huang Z, Karaboué A, Zeng L, Lecoeuvre A, Zhang L, Li XM, et al. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study. 2025. Available from: www.thelancet.com.
Ishizuka Y, Narita Y, Sakakida T, Wakabayashi M, Kodama H, Honda K, et al. Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer. Ther Adv Med Oncol. 2025;17:17588359251339921.
Google Scholar
Zheng Y, Shi F, Sun L, Guo J, Ren T, Ma J. Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis. Front Immunol. 2024;15:1512972.
Google Scholar
Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, et al. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026. Available from: https://www.nature.com/articles/s41591-025-04181-w.
Ascierto PA, Del Vecchio M, Merelli B, Gogas H, Arance AM, Dalle S, et al. Nivolumab for resected stage III or IV melanoma at 9 years. N Engl J Med. 2025. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2504966.
Patel SP, Kendra K, Grossmann KF, Buchbinder E, Khushalani NI, Eroglu Z, et al. 142P Infusion time of adjuvant PD-1 therapy in high-risk resectable melanoma: Accounting for distance from clinic, scheduling changes over time, and appropriately adjusting p-values in SWOG S1404. Immuno-Oncol Technol. 2025;28:101226.
Google Scholar
Landré T, Karaboué A, Buchwald ZS, Innominato PF, Qian DC, Assié JB, et al. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 2024;9:102220.
Innominato PF, Landré T, Karaboué A, Duchemann B, Buchwald ZS, Zhang YC, et al. Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration. JCO Oncol Pract. 2025. Available from: http://ascopubs.org/doi/10.1200/OP-25-00661.
Wang C, Zeng Q, Gül ZM, Wang S, Pick R, Cheng P, et al. Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. Cell. 2024;187:2690–2702.e17.
Google Scholar
Fortin BM, Pfeiffer SM, Insua-Rodríguez J, Alshetaiwi H, Moshensky A, Song WA, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:1257–69.
Google Scholar
Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016;27:1291–8.
Google Scholar
Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharm. 2014;78:106–17.
Google Scholar
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.
Google Scholar
Karaboué A, Innominato PF, Wreglesworth NI, Duchemann B, Adam R, Lévi FA. Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy? Br J Cancer. 2024;131:783–96.
Buchwald Z, Qian DC, Switchenko J, Yushak ML, Lawson DH, Lowe M. The TIME trial: phase II randomized controlled trial of time-of-day-specified immunotherapy for advanced melanoma. J Clin Oncol. 2025;43:TPS9601–TPS9601.
Özdemir BC, Bill R, Okyar A, Scheiermann C, Hayoz S, Olivier T. Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials. J ImmunoTher Cancer. 2025;13:e010644.
